

**amfAR**

MAKING AIDS HISTORY

2013 Annual Report  
amfAR, The Foundation for AIDS Research




# Contents

<b>amfAR in 2013: Program Highlights</b>	01
<b>Grants, Fellowships, and Awards</b>	04
Research Grants	
TREAT Asia Awards	
GMT Initiative Awards	
Public Policy Awards	
<b>Financial Highlights</b>	10
<b>Leadership and Advisory Committees</b>	12
Board of Trustees	
Scientific Advisory Committee	
Program Advisory Council	
Management Group	

**amfAR, The Foundation for AIDS Research,  
is dedicated to ending the global AIDS  
epidemic through innovative research.**

# amfAR in 2013: Program Highlights



## Research

- Much excitement surrounded the case of “the Mississippi child,” first reported by Dr. Deborah Persaud of Johns Hopkins Children’s Center in March 2013. A two-year-old child in Mississippi, born HIV positive, appeared to have been cured after being treated with antiretroviral therapy (ART) immediately after birth and then being taken off treatment. But during a routine clinical visit more than a year later, the child was found to have detectable levels of virus in the blood. The case will nonetheless remain an important landmark in AIDS research since no other child born with HIV is known to have spent as long off antiretroviral therapy without experiencing a resurgence of virus.
- amfAR continued to advance cure research through the amfAR Research Consortium on HIV Eradication (ARCHE). In 2013, the Foundation awarded nearly \$3 million to 12 collaborative research teams in the United States, United Kingdom, France, Thailand, and Australia working in the areas considered central to HIV eradication: expanding our understanding of latent viral reservoirs, developing a therapeutic vaccine, and examining pharmacological and gene therapy approaches to curing HIV.
- amfAR awarded nearly \$4 million in additional grants and fellowships to support 20 research projects. Many of these awards were for cure-focused studies aimed at answering critical questions such as how, where, and why does HIV persist in infected people taking ART. Four researchers received Mathilde Krim Fellowships in Basic Biomedical Research, which provide funding for exceptional young researchers who are new to the field of HIV/AIDS research.
- ARCHE grantees continued to build on previous progress made with amfAR funding. Dr. Eric Arts of Case Western Reserve University in Cleveland, Ohio, is aiming to develop and test an HIV treatment that is specific to each patient’s virus and targets the latent viral reservoir. A team led by Dr. Nicolas Chomont of the Vaccine and Gene Therapy Institute in Port St. Lucie, Florida, is investigating the roles CD4+ T memory cells—the cells where HIV reservoirs mainly reside—may play as a potential target for a cure. Dr. Jonah Sacha of the Oregon Health and Science

University in Portland is examining the macrophage—an immune cell that is closely related to the T cell—for its potential role in maintaining hidden reservoirs for HIV infection.

- amfAR convened a pair of think tanks in Amsterdam with European scientists in 2013. The first focused on the role of the immune system and immune-based therapies in attempts to eradicate HIV. The other led to the formation of a group of participating physicians and scientists committed to establishing a standard protocol for performing stem cell transplants in HIV-infected individuals who need them for reasons other than curing HIV.
- Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In 2013, close to 50 scientific publications resulted from amfAR-funded research.

## TREAT Asia

- TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) is a network of clinics, hospitals, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments throughout Asia and the Pacific. Facilitated by amfAR, TREAT Asia seeks to strengthen HIV/AIDS care, treatment, and management skills among healthcare professionals through education and training programs developed by experts in the region.
- In 2013, the TREAT Asia network began a regional study of hepatitis C co-infection among people living with HIV. The study aims to develop a pilot model of care for treating hepatitis C in resource-limited settings that can be replicated throughout the region, where treatment for the disease is costly and often inaccessible.
- TREAT Asia provided social support awards to four organizations in its pediatric network in 2013 to bolster their efforts to improve psychosocial support for HIV-positive young people, keep them in school, and ensure they receive age-appropriate medical treatment.



- With support from ViiV Healthcare, TREAT Asia is conducting an ongoing study using an audio-computer-assisted survey instrument (ACASI) to better understand how adolescents experience living with HIV by allowing them to anonymously respond to questions using a computer interface. Survey topics include whether or not they are taking their medicines; if they have tried alcohol, tobacco, or drugs; their sexual behavior; and stigma they may have experienced at school or at home.
- TREAT Asia organized five workshops and training sessions in 2013, including sessions on managing HIV and hepatitis C co-infection; good clinical practice and research ethics; and clinical management of pediatric HIV. In addition, TREAT Asia developed a series of educational materials about hepatitis C infection and treatment titled *Life Loves the Liver* that includes animated video segments, booklets, and flip charts on hepatitis C infection and treatment. All materials have been produced in Bahasa Indonesia, Chinese, English, Malay, Thai, and Vietnamese.



An image from *The Exchange*, amfAR's short documentary advocating for ending the ban on federal funding of syringe exchanges

## Public Policy

- Through its Public Policy office in Washington, D.C., amfAR educates policymakers, the media, and the public about evidence-based policies to address HIV/AIDS in the U.S. and around the world. In 2013, amfAR continued to promote rational AIDS-related policies based on the most current scientific knowledge.
- In 2013, amfAR produced four short films that illustrate the wide-ranging public health, public safety, and economic benefits of syringe services programs (SSPs) that combat the spread of HIV among people who inject drugs. The films support advocacy efforts aimed at overturning the ban on federal funding of SSPs.
- The Public Policy office produced a number of issue briefs, fact sheets, and infographics addressing the most pressing AIDS-related issues of 2013. Topics included addressing HIV among people who inject drugs and the value of SSPs; how budget cuts to national and international HIV treatment and research

programs undermine the domestic and global response to HIV; and strategies for tackling HIV among most-at-risk populations, which are often highly marginalized and difficult to access.

- In July 2013, amfAR held three Congressional briefings in Washington, D.C. Two of the briefings, which were co-sponsored with the Infectious Diseases Society of America's Center for Global Health Policy and the Elizabeth Glaser Pediatric AIDS Foundation, brought together leading researchers to discuss the cutting-edge science and evidence-based interventions needed to achieve an AIDS-free generation. The third discussed the need to end the ban on federal funding for SSPs to respond to rapidly increasing opiate use in the United States. The speakers included Seattle Police Chief Jim Pugel, Dr. Jennifer Havens of the University of Kentucky, and Kristin Dubay-Horton of the Bridgeport (CT) Health Department.
- amfAR developed *An Action Agenda to End AIDS*, a follow up to its 2012 Action Agenda released with AVAC at the International AIDS Conference. The report describes progress being made in certain areas, including increases in the total number of people on ART and the number of HIV-positive pregnant women receiving ART. The report also identifies areas where the global AIDS response is falling short, including the failure to scale up core HIV interventions in many areas and the failure to reduce widespread stigma and discrimination.

## GMT Initiative

- Since 2007, amfAR has been serving the HIV-related needs of gay men, other men who has sex with men (MSM), and transgender individuals (collectively, GMT) throughout the developing world through its GMT Initiative. Through small, targeted grants to grassroots groups, amfAR helps expand access to HIV education and prevention services; supports



Members of GMT Initiative grantee partner ASPIDH advocate for transgender rights in El Salvador. (Photo: ASPIDH)

advocacy aimed at increasing funding for prevention and treatment services; and works to end stigma, discrimination, and violence that threaten the lives of GMT and fuel the spread of HIV/AIDS.

- In 2013, amfAR awarded more than \$710,000 to 39 groups in Africa, the Caribbean, Eastern Europe and Central Asia, and Latin America. The awards support the work of grassroots groups working to reduce the spread and impact of HIV among GMT in hard hit regions of the developing world.
- The GMT Initiative made three awards as part of its Advocacy in Action program, which supports GMT-led community-based organizations that wish to influence the policies of governments and external donors. Four awards were made under its Evidence in Action program, which documents and evaluates the impact of community-based programs to better understand how to scale up the best strategies for stopping the spread of HIV among GMT. Evidence in Action was developed with support from ViiV Healthcare’s Positive Action Program and the Elton John AIDS Foundation. Awards for these two programs in 2013 totaled approximately \$150,000.
- In May 2013, amfAR published *Achieving an AIDS-Free Generation for Gay Men and Other MSM in Southern Africa*, with the Johns Hopkins Bloomberg School of Public Health. This report details how underfinancing, discrimination, and stigma undermine efforts to address HIV among GMT in the region and makes recommendations about how policymakers can better address the needs of GMT. Individual country profiles on Botswana, Malawi, Namibia, Swaziland, Zambia, and Zimbabwe were also produced to supplement the report.
- The GMT Initiative Blog, *Grassroots*, posted articles throughout the year that discuss how various HIV-related issues impact the GMT Initiative grantee partners’ lives and work.

## Public Information

- amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS-related press coverage. Articles and reports involving amfAR—many of which included interviews with amfAR spokespeople—were carried in numerous media outlets, including *The New York Times*, *The Wall Street Journal*, *The Washington Post*, the Associated Press, Reuters, Bloomberg News, CNN, and *The Huffington Post*.



amfAR Ambassador Milla Jovovich, amfAR Global Fundraising Chairman Sharon Stone, and Jessica Chastain during the 2013 Cinema Against AIDS gala (Photo: Kevin Tachman)

- amfAR has long benefited from the voices and the visibility of a wide range of prominent public figures. In 2013, celebrity supporters included amfAR Global Fundraising Chairman Sharon Stone, amfAR ambassadors Cheyenne Jackson, Janet Jackson, Milla Jovovich, Liza Minnelli, and Michelle Yeoh, as well as Leonardo DiCaprio, Heidi Klum, Alan Cumming, Aishwarya Rai, Abhishek Bachchan, Jessica Chastain, Hilary Swank, Kylie Minogue, Rosario Dawson, Rosie Perez, Zachary Quinto, Adrien Brody, Dita Von Teese, and Chelsea Handler, among many others.
- *The Battle of amfAR*, a documentary telling the story of how Swiss scientist Dr. Mathilde Krim and Hollywood movie star Elizabeth Taylor joined forces to create amfAR in 1985, was screened at prominent film festivals throughout 2013 and was an Official Selection at the Sundance and Tribeca Film Festivals. It was produced by amfAR Chairman Kenneth Cole and premiered on HBO in December 2013.
- amfAR’s Public information team produces a range of educational materials, program reports, and periodicals in an effort to communicate the Foundation’s message and the need for AIDS research. Its 2013 publications included: *Innovations*, amfAR’s newsletter; the *TREAT Asia Report*, which is distributed widely to an international audience; and a monthly e-mail newsletter sent to more than 100,000 subscribers.
- The amfAR website features news, interviews, editorials, and blog posts covering research, policy, and amfAR’s programs and activities. The Foundation also spreads its message on social media and has over 45,000 likes on Facebook, 20,000 Twitter followers, and 6,000 Instagram followers.

## 2013 RESEARCH FELLOWSHIPS, GRANTS, AND AWARDS

All projects listed below were awarded amfAR funding during the period October 1, 2012, through September 30, 2013.

### AMFAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE)

#### Activation of latent HIV using an autologous HIV vector

Principal Investigator: Eric Arts, Ph.D.  
Case Western Reserve University  
Cleveland, OH  
\$349,964

#### Identifying and targeting HIV persistence in T cell subsets during ART

Principal Investigator: Nicolas Chomont, Ph.D.  
Vaccine and Gene Therapy Institute of Florida  
Port St. Lucie, FL  
\$590,285

#### Programming stem cells with a chimeric antigen receptor to eradicate HIV

Principal Investigator: Scott Kitchen, Ph.D.  
University of California, Los Angeles  
Los Angeles, CA  
\$300,000

#### HIV antigen within the latent reservoir: a new assay for eradication trials

Principal Investigator: David Margolis, M.D.  
The University of North Carolina at Chapel Hill  
Chapel Hill, NC  
\$166,748

#### Evaluating the threat posed by intact, non-induced proviruses

Principal Investigator: Robert F. Siliciano, M.D., Ph.D.  
Johns Hopkins University  
Baltimore, MD  
\$180,000

### MATHILDE KRIM FELLOWS IN BASIC BIOMEDICAL RESEARCH

#### Preventing HIV Transmission

##### Cross-species transmission events that led to the HIV-1 pandemic

Principal Investigator: Lucie Etienne, Ph.D.  
Fred Hutchinson Cancer Research Center  
Seattle, WA  
\$125,000

##### Structural studies of glycan-specific sites of vulnerability on HIV-1 gp120

Principal Investigator: Leopold Kong, D.Phil.  
The Scripps Research Institute  
La Jolla, CA  
\$125,000

#### Pursuing HIV Eradication

##### Impact of cancer and transplant therapy on HIV-1 reservoirs

Principal Investigator: Christine Durand, M.D.  
Johns Hopkins University  
Baltimore, MD  
\$125,000  
\$80,000 (Phase II)

#### Optimizing Treatment

##### Dissecting the mechanism of HIV-1 entry inhibition by novel small molecules

Principal Investigator: Alon Herschhorn, Ph.D.  
Dana-Farber Cancer Institute  
Boston, MA  
\$125,000

### RESEARCH GRANTS

#### Pursuing HIV Eradication

##### Immune correlates of viral rebound after therapeutic HIV vaccination

Principal Investigator: Christian Brander, Ph.D.  
Fundación IRSICAIXA  
Barcelona, Spain  
\$180,000

##### Sorted bead sequencing to accurately assess HIV in reservoirs

Principal Investigator: James Mullins, Ph.D.  
University of Washington  
Seattle, WA  
\$180,000

##### HIV-1 cellular immunity during serial and repetitive panobinostat dosing

Principal Investigator: Lars Ostergaard, M.D., Ph.D., DMSc  
Aarhus University  
Aarhus, Denmark  
\$180,000

##### Effects of CCR5-Δ32 heterozygosity on the HIV-1 reservoir

Principal Investigator: Satish Pillai, Ph.D.  
Regents of the University of California, San Francisco  
\$178,753  
Blood Systems, Inc.  
\$168,773 (transfer)

##### Plasmacytoid dendritic cells in immune activation and HIV/SIV persistence

Principal Investigator: Roger Keith Reeves, Ph.D.  
New England Primate Research Center, President and Fellows of Harvard College  
Southborough, MA  
\$178,800

##### The role of macrophages as a latent reservoir of HIV

Principal Investigator: Jonah Sacha, Ph.D.  
Oregon Health and Science University  
Portland, OR  
\$180,000

##### Impact of ZFN CCR5-modified autologous CD4 T-cells on HIV persistence

Principal Investigator: Rafick-Pierre Sékaly, Ph.D.  
Vaccine and Gene Therapy Institute of Florida  
Port St. Lucie, FL  
\$179,984

##### Impact of CMV replication on HIV latent reservoir

Principal Investigator: Sara Gianella Weibel, M.D.  
Veterans Medical Research Foundation  
San Diego, CA  
\$180,000

### RESEARCH WORKSHOPS AND MEETINGS

#### The International Workshop on HIV Dynamics and Evolution

Principal Investigator: Steven Wolinsky, M.D.  
Northwestern University  
Chicago, IL  
\$5,850

## 2013 TREAT ASIA GRANTS AND AWARDS

\*Supported by National Institutes of Health under National Institutes of Health cooperative agreement number U01AI069907 with funds from the National Institute of Allergy and Infectious Diseases, the National Cancer Institute, and the Eunice Kennedy Shriver National Institute of Child Health and Development.

\*\*Supported by National Institutes of Health grant number 5R01HD073972 with funds from the Eunice Kennedy Shriver National Institute of Child Health and Development.

### ADULT RESEARCH

#### TREAT ASIA HIV OBSERVATIONAL DATABASE (TAHOD)

Romane Chaiwarith, M.D., M.H.S.  
Chiang Mai University - Research Institute for Health Sciences  
Chiang Mai, Thailand  
\$20,000\*

Jun Yong Choi, M.D., Ph.D.  
Yonsei University College of Medicine  
Seoul, South Korea  
\$16,500\*

Rossana Ditangco, M.D.  
Asian Foundation for Tropical Medicine, Inc.  
Muntinlupa City, Philippines  
\$20,000\*

Adeeba Kamarulzaman, M.B.B.S., F.R.A.C.P.  
University of Malaya  
Kuala Lumpur, Malaysia  
\$20,000\*

Pacharee Kantipong, M.D.  
Chiangrai Prachanukroh Hospital  
Chiang Rai, Thailand  
\$6,750\* (year 7)/\$13,500\* (year 8)

Sasisopin Kiertiburanakul, M.D., M.H.S.  
Ramathibodi Hospital, Mahidol University  
Bangkok, Thailand  
\$20,000\*

Nagalingeswaran Kumarasamy, M.D., M.B.B.S., Ph.D.  
YRG Centre for AIDS Research and Education, VHS  
Chennai, India  
\$20,000\*  
Christopher Lee, M.B.B.S., M.R.C.P.  
Sungai Buloh Hospital  
Sungai Buloh, Malaysia  
\$15,000\*

Patrick Li, M.B.B.S.  
Queen Elizabeth Hospital  
Hong Kong, China  
\$20,000\*

Tuti Parwati Merati, M.D., Ph.D.  
Udayana University School of Medicine  
Denpasar, Indonesia  
\$18,500\*

Shinichi Oka, M.D., Ph.D.  
National Center for Global Health and Medicine  
Shinjuku, Japan  
\$16,000\*

Oon Tek Ng, M.B.B.S., M.R.C.P., M.P.H.  
Tan Tock Seng Hospital  
Singapore, Singapore  
\$16,000\*

Praphan Phanuphak, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$20,000\*

Sanjay Pujari, M.D., AAHIVS  
Institute of Infectious Diseases  
Pune, India  
\$20,000\*

Winai Ratanasuwan, M.D.  
Siriraj Hospital, Mahidol University  
Bangkok, Thailand  
\$7,500\* (year 7)/\$7,350\* (year 8)

Pham Thi Thanh Thuy, M.D., Ph.D.  
Bach Mai Hospital  
Hanoi, Vietnam  
\$20,000\*

Nguyen Van Kinh, M.D., Ph.D.  
National Hospital of Tropical Diseases  
Hanoi, Vietnam  
\$20,000\*

Saphonn Vonthanak, M.D., Ph.D.  
National Center for HIV/AIDS, Dermatology &  
STDs  
Cambodia National Institute of Public Health  
Phnom Penh, Cambodia  
\$20,000\*

Wing-Wai Wong, M.D., Sc.D  
Taipei Veterans General Hospital  
Taipei City, Taiwan, Republic of China  
\$20,000\*

Evy Yunihastuti, M.D., Ph.D.  
Cipto Mangunkusumo General Hospital  
Jakarta, Indonesia  
\$20,000\*

Fujie Zhang, M.D., M.P.H.  
Beijing Ditan Hospital, Capital Medical University  
Beijing, China  
\$16,000\*

#### **TAHOD STUDY ON THE SOCIO-ECONOMIC DETERMINANTS OF TUBERCULOSIS IN ASIA**

Rossana Ditangco, M.D.  
Asian Foundation for Tropical Medicine, Inc.  
(as intermediary for the Research Institute of  
Tropical Medicine)  
Muntinlupa City, Philippines  
\$900\*

Adeeba Kamarulzaman, M.B.B.S., F.R.A.C.P.  
University of Malaya  
Kuala Lumpur, Malaysia  
\$1,300\*

Sasisopin Kiertiburanakul, M.D., M.H.S.  
Ramathibodi Hospital, Mahidol University  
Bangkok, Thailand  
\$500\*

Christopher Lee, M.B.B.S., M.R.C.P  
Sungai Buloh Hospital  
Sungai Buloh, Malaysia  
\$6,870\* (year 1)/\$600\* (year 2)

Patrick Li, M.B.B.S.  
Queen Elizabeth Hospital  
Hong Kong, China  
\$300\*

Tuti Parwati Merati, M.D., Ph.D.  
Udayana University School of Medicine  
Denpasar, Indonesia  
\$4,600\*

Oon Tek Ng, M.B.B.S., M.R.C  
Tan Tock Seng Hospital  
Singapore, Singapore  
\$1,050\*

Praphan Phanuphak, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$500\*

Phạm Thị Thanh Thủy M.D., Ph.D.  
Bach Mai Hospital  
Hanoi, Vietnam  
\$3,550\*

Nguyen Van Kinh, M.D., Ph.D.  
National Hospital of Tropical Diseases  
Hanoi, Vietnam  
\$3,700\*

Wing-Wai Wong, M.D.  
Taipei Veterans General Hospital  
Taipei City, Taiwan, Republic of China  
\$900\* (year 1)/\$1,500\* (year 2)

Evy Yunihastuti, M.D., Ph.D.  
Cipto Mangunkusumo General Hospital  
Jakarta, Indonesia  
\$1,850\*

Fujie Zhang, M.D.  
Beijing Ditan Hospital, Capital Medical University  
Beijing, China  
\$3,000\*

#### **AUSTRALIA HIV OBSERVATIONAL DATABASE (AHOD)**

Debbie Allen, M.B.Ch.B., Dip.  
Central Coast Local Health District  
Holden Street Clinic  
Gosford, Australia  
\$1,500

David Baker, B.H.B.  
East Sydney Doctors  
Darlinghurst, Australia  
\$7,500\*†

Mark Bloch, M.D.  
Holdsworth House Medical Practice  
Darlinghurst, Australia  
\$6,300\*†

Katherine Brown, M.D.  
Illawarra Shoalhaven Local Health District  
Wollongong, Australia  
\$1,425

David Cooper, M.D.  
St. Vincent's Hospital Sydney Limited  
Darlinghurst, Australia  
\$6,825\*

William Donohue, M.B.B.S.  
O'Brien Street Practice  
Adelaide, Australia  
\$1,575

David Ellis, M.B.B.S.  
D.A. Ellis, Pty., Ltd.  
Coffs Harbour, Australia  
\$750†

Robert Finlayson, M.B.B.S., Dip. Ven.  
Taylor Square Private Clinic  
Darlinghurst, Australia  
\$5,775\*†

Jennifer Hoy, M.B.B.S.  
Victorian HIV Service, Infectious Diseases  
Department  
The Alfred Hospital  
Melbourne, Australia  
\$6,075\*

Eva Jackson, M.B.B.S.  
Blue Mountains Sexual Health and HIV Clinic  
Katoomba, Australia  
\$1,050

Mark Kelly, M.B.B.S.  
Prince Charles Hospital  
Brisbane Sexual Health and HIV Service  
Brisbane, Australia  
\$4,950\*

Richard Moore  
Northside Clinic (Vic), Pty., Ltd.  
North Fitzroy, Australia  
\$7,500\*†

David Nolan  
Royal Perth Hospital  
Perth, Australia  
\$4,950\*

David Orth, M.B., B.S., Dip. Ven.  
Gladstone Road Medical Centre  
Highgate Hill, Australia  
\$4,800\*†

Tim Read  
Melbourne Sexual Health Centre  
Carlton, Australia  
\$5,175\*

Norman Roth, M.B.B.S., F.A.Ch.S.H.M.  
Prahlan Market Clinic, Pty., Ltd.  
South Yarra, Australia  
\$6,000\*

Darren Russell, M.D.  
Cairns Sexual Health Service  
Cairns, Australia  
\$5,175\*

Nathan Ryder, M.D.  
Northern Territory Dept of Health & Community  
Services  
Sexual Health & Blood Borne Virus Program  
Darwin, Australia  
\$900

David Smith  
Sexual Health and AIDS Services  
Lismore, Australia  
\$6,600\*

David Sowden, M.B.B.S  
Sunshine Coast Hospital and Health Service  
Nambour, Australia  
\$7,500\*

Sharon Taylor, C.N.C.  
Hunter New England Health  
Tamworth Sexual Health Service  
Tamworth, Australia  
\$900

David Templeton, Ph.D.  
RPA Sexual Health Clinic  
Camperdown, Australia  
\$750



Rick Varma, M.R.C.P.  
Nepean Sexual Health Clinic  
Kingswood, Australia  
\$900

Ian Woolley, M.B.B.S., F.R.A.C.P.  
Monash Health, Monash Medical Centre - Clayton  
Melbourne, Australia  
\$4,125\*

Lynne Wray, M.B.B.S.  
Sydney Sexual Health Centre, Sydney Hospital  
Sydney, Australia  
\$4,575\*

† funding to private medical practices provided by  
program technical support agreements

#### **HCV STUDY PREPARATION AWARD**

Adeeba Kamarulzaman, M.B.B.S., F.R.A.C.P.  
University of Malaya  
Kuala Lumpur, Malaysia  
\$3,500

Kiat Ruxrungtham, M.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$3,500

Nguyen Van Kinh, M.D., Ph.D.  
National Hospital of Tropical Diseases  
Hanoi, Vietnam  
\$3,500

Evy Yunihastuti, M.D., Ph.D.  
Cipto Mangunkusumo General Hospital  
Jakarta, Indonesia  
\$3,500

#### **EFFECTIVENESS AND TOLERABILITY OF HCV TREATMENT IN HIV CO-INFECTED PATIENTS: SCREENING**

Adeeba Kamarulzaman, M.B.B.S., F.R.A.C.P.  
University of Malaya  
Kuala Lumpur, Malaysia  
\$25,200\*

Kiat Ruxrungtham, M.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$25,200\*

Nguyen Van Kinh, M.D., Ph.D.  
National Hospital of Tropical Diseases  
Hanoi, Vietnam  
\$25,200\*

Evy Yunihastuti, M.D., Ph.D.  
Cipto Mangunkusumo General Hospital  
Jakarta, Indonesia  
\$29,700\*

#### **(Individual projects)**

##### **Clinical epidemiology of cancer among PLHA in Taiwan**

Yi-Ming Chen, M.D., Sc.D.  
Kaohsiung Medical University  
Kaohsiung, Taiwan, Republic of China  
\$15,167\* (year 2)/\$30,000\* (year 3)

##### **Clinical epidemiology of cancer among PLHA in Taiwan**

Yi-Ming Chen, M.D., Sc.D.  
National Yang-Ming University  
Taipei, Taiwan, Republic of China  
\$20,300\*

##### **Clinical epidemiology of tuberculosis infection among PLWHA in Taiwan**

Yi-Ming Chen, M.D., Sc.D.  
Kaohsiung Medical University  
Kaohsiung, Taiwan, Republic of China  
\$19,042\*

##### **Clinical epidemiology of tuberculosis infection among PLWHA in Taiwan**

Yi-Ming Chen, M.D., Sc.D.  
National Yang-Ming University  
Taipei, Taiwan, Republic of China  
\$26,800\*

##### **Asia Pacific HIV research collaboration: AHOD, HCV outcomes**

Matthew G. Law, Ph.D.  
University of New South Wales  
Sydney, Australia  
\$241,548\*

##### **Asia Pacific HIV research collaboration: cancer studies**

Matthew G. Law, Ph.D.  
University of New South Wales  
Sydney, Australia  
\$44,271\*

##### **Asia Pacific HIV research collaboration: TAHOD**

Matthew G. Law, Ph.D.  
University of New South Wales  
Sydney, Australia  
\$221,907\*

##### **Identifying biomarkers of anal intraepithelial neoplasia in Thai MSM**

Nittaya Phanuphak, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$15,000\*/\$95,000\*

##### **Study on anal human papillomavirus infection and anal intraepithelial neoplasia among men who have sex with men in Indonesia, Malaysia, and Thailand**

Nittaya Phanuphak, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$36,098\*

#### **PEDIATRIC RESEARCH**

##### **TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TAPHOD)**

Torsak Bunupuradah, M.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$15,740\*

Kulkanya Chokephaibulkit, M.D.  
Siriraj Hospital, Mahidol University  
Bangkok, Thailand  
\$17,165

Rawiwan Hansudewechakul, M.D.  
Chiangrai Prachanukroh Hospital  
Chiang Rai, Thailand  
\$24,050

Trương Hữu Khanh, M.D.  
Children's Hospital 1  
Ho Chi Minh City, Vietnam  
\$26,850

Nagalingeswaran Kumarasamy, M.D., M.B.B.S.  
YRG Centre for AIDS Research and Education,  
VHS  
Chennai, India  
\$9,715

Nia Kurniati, M.D.  
Cipto Mangunkusumo General Hospital  
Jakarta, Indonesia  
\$10,650

Pagakrong Lumbiganon, M.D.  
Srinagarind Hospital, Khon Kaen University  
Khon Kaen, Thailand  
\$15,890

Fong Siew Moy, M.D.  
Hospital Likas  
Kota Kinabalu, Malaysia  
\$5,000 (supplemental funding year 6)/  
\$7,545 (year 7)

Revathy Nallusamy, M.B.B.S.  
Penang Hospital  
Georgetown, Malaysia  
\$2,695

Kamarul Razali, M.D.  
Pediatric Institute, Hospital Kuala Lumpur  
Kuala Lumpur, Malaysia  
\$9,150

Virat Sirisanthana, M.D.  
Chiang Mai University  
Research Institute for Health Sciences  
Chiang Mai, Thailand  
\$16,760\*

Ketut Dewi Kumara Wati, M.D.  
Udayana University School of Medicine  
Denpasar, Indonesia  
\$5,000 (supplemental funding year 6)/\$8,105

Nguyen Van Lam, M.D.  
National Hospital of Pediatrics  
Hanoi, Vietnam  
\$21,500

Do Chau Viet, M.D.  
Children's Hospital 2  
Ho Chi Minh City, Vietnam  
\$15,860

Saphonn Vonthanak, M.D.  
National Center for HIV/AIDS, Dermatology &  
STDs  
Cambodia National Institute of Public Health  
Phnom Penh, Cambodia  
\$33,445

Nik Khairulddin Nik Yusoff, M.D.  
Hospital Raja Perempuan Zainab II  
Kota Bharu, Malaysia  
\$1,920 (supplemental funding year 6)/  
\$8,055 (year 7)

##### **TREAT ASIA STUDIES TO EVALUATE RESISTANCE – PEDIATRICS (TASER-P)**

Kulkanya Chokephaibulkit, M.D.  
Siriraj Hospital, Mahidol University  
Bangkok, Thailand  
\$13,500

Trương Hữu Khanh, M.D.  
Children's Hospital 1  
Ho Chi Minh City, Vietnam  
\$22,500

Pope Kosalaraksa, M.D.  
Srinagarind Hospital, Khon Kaen University  
Khon Kaen, Thailand  
\$2,090 (supplement year 3)/\$13,500 (year 4)

Nia Kurniati, M.D.  
Cipto Mangunkusumo General Hospital  
Jakarta, Indonesia  
\$460 (supplement year 3 /\$13,500 (year 4)

Wasana Prasitsuebsai, M.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$18,500

Virat Sirisanthana, M.D.  
Chiang Mai University  
Research Institute for Health Sciences  
Chiang Mai, Thailand  
\$110 (supplement year 3)/\$9,500 (year 4)

Nguyen Van Lam, M.D., M.S.C.  
National Hospital of Pediatrics  
Hanoi, Vietnam  
\$18,500

Do Chau Viet, M.D.  
Children's Hospital 2  
Ho Chi Minh City, Vietnam  
\$20,500

**UNDERSTANDING ADHERENCE, STIGMA,  
AND BEHAVIORAL RISK FACTORS OF  
ADOLESCENTS IN TAPHOD USING AUDIO  
COMPUTER ASSISTED SELF-INTERVIEW  
(ACASI)**

Jintanat Ananworanich, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
(as study site)  
Bangkok, Thailand  
\$4,645\* (year 1)/\$5,475\* (year 2)

Kulkanya Chokephaibulkit, M.D.  
Siriraj Hospital Mahidol University  
Bangkok, Thailand  
\$4,675\* (year 1)/\$5,292\* (year 2)

Rawiwan Hansudewechakul, M.D.  
Chiangrai Prachanukroh Hospital  
Chiang Rai, Thailand  
\$4,810\* (year 1)/\$5,050\* (year 2)

Trương Hữu Khanh, M.D.  
Children's Hospital 1  
Ho Chi Minh City, Vietnam  
\$4,400\*

Pagakrong Lumbiganon, M.D.  
Srinagarind Hospital, Khon Kaen University  
Khon Kaen, Thailand  
\$4,475\* (year 1)/\$3,635\* (year 2)

Fong Siew Moy, M.D.  
Hospital Likas  
Kota Kinabalu, Malaysia  
\$1,300\* (year 1)/\$1,500\* (year 2)

Wasana Prasitsuebsai, M.D., M.P.H.  
HIV-NAT/Thai Red Cross AIDS Research Center  
(as data management center)  
Bangkok, Thailand  
\$8,000\*

Kamarul Razali, M.D.  
Pediatric Institute, Hospital Kuala Lumpur  
Kuala Lumpur, Malaysia  
\$2,100\* (year 1)/\$1,700\* (year 2)

Nguyen Van Lam, M.D., M.S.C.  
National Hospital of Pediatrics  
Hanoi, Vietnam  
\$4,200\* (year 1)/\$2,800\* (year 2)

Nik Khairulddin Nik Yusoff, M.D.  
Hospital Raja Perempuan Zainab II  
Kelantan, Malaysia  
\$2,000\* (year 1)/\$2,100\* (year 2)

**HUMAN PAPILLOMAVIRUS (HPV) INFECTION IN  
PERINATALLY HIV-INFECTED ADOLESCENTS  
IN ASIA**

Jintanat Ananworanich, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
(as study site)  
Bangkok, Thailand  
\$17,250\*\* (year 1)/\$32,175\*\* (year 2)

Kulkanya Chokephaibulkit, M.D.  
Siriraj Hospital Mahidol University  
Bangkok, Thailand  
\$24,900\*\* (year 1)/\$59,076\*\* (year 2)

Rawiwan Hansudewechakul, M.D.  
Chiangrai Prachanukroh Hospital  
Chiang Rai, Thailand  
\$49,505\*\*

Thoa Kim Le Phan, M.D.  
Children's Hospital 1  
Ho Chi Minh City, Vietnam  
\$20,885\*\*

Nittaya Phanuphak, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
(as data management center)  
Bangkok, Thailand  
\$125,362\*\* (year 1)/\$220,255\*\* (year 2)

Nguyen Van Truong, M.D.  
Hung Vuong Hospital  
Ho Chi Minh City, Vietnam  
\$50,095\*\*

**TRANSITIONING FROM PEDIATRIC TO ADULT  
HIV CARE IN THAILAND AND VIETNAM**

Kulkanya Chokephaibulkit, M.D.  
Siriraj Hospital, Mahidol University  
Bangkok, Thailand  
\$729

Rawiwan Hansudewechakul, M.D.  
Chiangrai Prachanukroh Hospital  
Chiang Rai, Thailand  
\$1,010

Trương Hữu Khanh, M.D.  
Children's Hospital 1  
Ho Chi Minh City, Vietnam  
\$700

*(Individual projects)*

**CHAMP+ Asia Study**

Jintanat Ananworanich, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$40,000\* (year 1)/\$35,000\* (year 2)

**Effect of socioeconomic factors on cognition,  
adaptive function and school status**

Jintanat Ananworanich, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$57,276

**Promote early disclosure of HIV status in Thai  
children with perinatal HIV infection**  
Jintanat Ananworanich, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$15,000

**HIV and HBV co-infection among perinatally  
HIV-infected adolescents in Asia: whole  
genome sequencing**

Linda Aurrpibul, M.D.  
Chiang Mai University  
Chiang Mai, Thailand  
\$3,000\*

**Bone mineral density among HIV-Infected  
adolescents**

Kulkanya Chokephaibulkit, M.D.  
Siriraj Hospital, Mahidol University  
Bangkok, Thailand  
\$3,253\*

**Cardiovascular abnormalities and carotid intima-  
media thickness among HIV-infected adolescents  
in Thailand (supplemental funding)**

Kulkanya Chokephaibulkit, M.D.  
Siriraj Hospital, Mahidol University  
Bangkok, Thailand  
\$5,000

**Social support award for children and  
adolescents with HIV**

Rawiwan Hansudewechakul, M.D.  
Chiangrai Prachanukroh Hospital  
Chiang Rai, Thailand  
\$14,702

**Comparing interventions to improve  
cART adherence of HIV+ adolescents  
and young adults**

Stephen Kerr, Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$105,491

**Asia Pacific HIV Research Collaboration: TAPHOD**

Matthew G. Law, Ph.D.  
University of New South Wales  
Sydney, Australia  
\$237,874\*

**Social support award 2013–2014**

Fong Siew Moy, M.D.  
Hospital Likas  
Kota Kinabalu, Malaysia  
\$5,650

**Social support for children and adolescents with  
HIV for Penang Site, Malaysia**

Revathy Nallusamy, M.B.B.S.  
Penang Hospital  
Georgetown, Malaysia  
\$4,481

**Support caregivers and social workers to improve  
disclosure process to HIV+ children**

Le Ngoc Oanh, M.D.  
Worldwide Orphans Foundation  
Maplewood, NJ  
\$14,927

**Prevalence of HLA-B\*5701 among HIV-infected  
children in Thailand and Cambodia: implications  
for abacavir use**

Thanyawee Puthanakit, M.D.  
HIV-NAT / Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$15,964

## Our Village

John Tucker  
New Hope for Cambodian Children  
Killeen, Texas  
\$39,029

## Hepatitis B testing

John Tucker  
New Hope for Cambodian Children  
Killeen, TX  
\$3,630

## Training for early disclosure for children and adolescents in National Pediatric Hospital

Vibol Ung, M.D.  
National Pediatric Hospital  
Phnom Penh, Cambodia  
\$9,820

## 2013 GMT INITIATIVE AWARDS

### Africa

#### Improving social and health conditions for LGBTI sex workers in Bukavu/South Kivu Province in the Democratic Republic of Congo

Humanitarian Action for Health and Community Development (AHUSADEC)  
Bukavu, DRC  
\$19,984

#### Reducing HIV vulnerability and the disease burden through economic viability among the GMT population within Kisumu County

Men Against AIDS Youth Group (MAAYGO)  
Kisumu, Kenya  
\$20,000

#### Enhancing ARV adherence for gay men, MSM, and transgender (GMT) individuals and male sex workers (MSW) in Kenya

Health Options for Young Men on HIV, AIDS and STIs (HOYMAS)  
Nairobi, Kenya  
\$20,000

#### GMT sexual health advocacy and rights project (G-SHARP)

Stop AIDS in Liberia (SAIL)  
Monrovia, Liberia  
\$20,000

#### Al Borj Center for Reproductive and Sexual Health

Name Witheld by Request  
Marrakesh, Morocco  
\$20,000

#### Creating space for MSM to dialogue with policymakers on national and state plans for MSM HIV prevention and treatment

New HIV Vaccine and Microbicide Advocacy Society (NHVMAS)  
Lagos, Nigeria  
\$19,789

#### Engaging MSM in advocating for the implementation of national policies that ensure access to comprehensive HIV prevention

Health Development Initiative-Rwanda (HDI)  
Kigali, Rwanda  
\$19,980

#### Accreditation of training manual to provide competent services to GMT individuals

OUT Lesbian/Gay/Bisexual/Transgender (LGBT) Wellbeing  
Pretoria, South Africa  
\$18,500

#### Transgender HIV and sexual health research and awareness project

Transgender and Intersex Africa  
Pretoria, South Africa  
\$20,000

#### Strengthening healthcare access for GMT in Swaziland

Rock of Hope  
Manzini, Swaziland  
\$22,000

#### Capacity strengthening and advocacy for MSM organizations in Togo

MEN'S  
Lomé, Togo  
\$20,000

#### GMT health is a human right

Spectrum Uganda Initiatives, Inc.  
Kampala, Uganda  
\$20,000

### Caribbean

#### Working together to enhance the MSM community in Antigua and Barbuda II

Antigua Resilience Collective, Inc. (ARC)  
St. John's, Antigua and Barbuda  
\$14,700

#### Dominica healthy men (DO-HEM) project

Dominica Planned Parenthood Association  
Roseau, Dominica  
\$19,250

#### Píldoras para la vida (Pills for life)

Comunidad de Trans Travesti Trabajadoras Sexuales Dominicanas (COTRAVETD)  
San Carlos, Dominican Republic  
\$17,500

#### Education and testing to reduce HIV and HPV disease in Dominican MSM/transgender

Instituto Dominicano de Estudios Virologicos (IDEV)  
Santo Domingo, Dominican Republic  
\$17,500

#### Strengthening the community response, access to care and treatment

The Network of Guyanese Living with and Affected by HIV/AIDS (G+)  
Georgetown, Guyana  
\$17,494

#### Owning our courage: enhancing GMT organizing efforts in Haiti

KOURAJ Pou Pwoteje Dwa Moun  
Port au Prince, Haiti  
\$17,500

#### Across the lines

The Ashe Company  
Kingston, Jamaica  
\$17,496

#### Get up, stand up

Jamaica AIDS Support for Life (JASL)  
Kingston, Jamaica  
\$17,500

#### Fight the hate: mitigating risks and enabling safe spaces for LGBT Jamaicans (phase II)

Jamaica Forum for Lesbians, All-Sexuals & Gays (J-FLAG)  
Kingston, Jamaica  
\$17,500

### Latin America

#### If you saw your mother (Si te viera tu madre)

Red de personas viviendo con VIH/SIDA Mar del Plata/ATTTA Costa atlantica  
Mar Del Plata, Argentina  
\$19,900

#### Gender identity law for Bolivia: my identity my right

Red Nacional De Mujeres Trans (RED TREBOL)  
Cochabamba, Bolivia  
\$20,000

#### Advocacy during the electoral process for resource mobilization in order to respond to HIV/AIDS in GMT and fight homophobia

CES/MUMS Movimiento Por la Diversidad Sexual  
Santiago, Chile  
\$20,000

#### Working for a dignified life free of stigma and discrimination for women

Colectivo Unidad Color Rosa  
San Pedro Sula, Honduras  
\$19,859

#### Closing the gaps, integrating communities (phase II)

Asociación Jóvenes en Movimiento (AJEM)  
Tegucigalpa, Honduras  
\$20,000

#### Strengthening community health services for transgender people

Centro de Desarrollo e Investigación sobre Juventud, A.C.  
Campeche, Mexico  
\$20,000

#### Indigenous youth MSM and inclusive schools against HIV

Interculturalidad, Salud y Derechos A.C. (INSADE)  
Mexico City, Mexico  
\$14,440

#### Promoting access to culturally appropriate HIV services and healthcare for gay men and transgender women in Iquitos through public policy change

Gay Youth in Action against AIDS (GYAA )  
Iquitos, Peru  
\$20,000

### Eastern Europe and Central Asia

#### Mainstreaming HIV/AIDS prevention activities for GMT in Armenia through holistic approaches

We for Civil Equality (WFCE)  
Yerevan, Armenia  
\$14,982

#### Introduction of the innovative VCT methodologies for the MSM population

Association Partnerships in Health (PIH)  
Sarajevo, Bosnia-Herzegovina  
\$14,280

#### Coming out

Public Association "Azimut Plus"  
Karaganda, Kazakhstan  
\$15,050

#### Security for LGBT: fighting against violence and promoting human rights

Kyrgyz Indigo  
Bishkek, Kyrgyzstan  
\$19,952

#### On a positive wave

Public Association Pathfinder  
Bishkek, Kyrgyzstan  
\$14,995

#### GMT mobilization and integration to improve the secondary health system

Association for Support of Marginalized Workers  
STAR-STAR Skopje  
Skopje, Macedonia  
\$12,000

#### Improving GMT individuals' access to HIV testing in Montenegro

Juventas  
Podgorica, Montenegro  
\$14,920

#### Multimodal approach to HIV and STI prevention at primary and secondary levels among the GMT population in Belgrade

Safe Pulse of Youth (SPY)  
Belgrade, Serbia  
\$20,000

#### Reduction of HIV transmission and support for GMT

Q-Club  
Belgrade, Serbia  
\$15,000

#### Accessible, quality, and reliability, on equal terms Equal Opportunities (EO)

Dushanbe, Tajikistan  
\$20,200

#### ADVOCACY IN ACTION AWARDS

##### Mainstreaming LGBT issues into national healthcare and service delivery

Lesbians, Gays and Bisexuals of Botswana (LEGABIBO)  
Gaborone, Botswana  
\$20,000

##### Advocacy for appropriate healthcare needs for MSM in the city of Yaoundé

Humanity First Cameroon  
Yaoundé, Cameroon  
\$15,000

##### Advocacy in action 2.0 China 2013 Chengdu Love & Kindness Group

Chengdu Ai Ren Tong Meng  
Chengdu, China  
\$17,000

##### Advocacy for access to education for trans women

Asociación Silueta X  
Guayaquil, Ecuador  
\$15,000

##### Advocacy in action 2.0 Lao PDR 2013

Lao Positive Health Association (LaoPHA)  
Vientiane, Lao PDR  
\$18,000

##### Advocacy in action 2.0 Thailand 2013

Health and Opportunity Network (HON)  
Bangkok, Thailand  
\$18,135

#### EVIDENCE IN ACTION AWARDS

##### Improving access to HIV and STI prevention and care services amongst GMT in Belize

Collaborative Network of Persons Living with HIV (C-NET+)  
Belize City, Belize  
\$26,594

##### Phase 2: medical, psychological and HIV/AIDS prevention for MSM

Asociación ALFIL  
Quito, Ecuador  
\$24,066

##### Abriendo caminos 2.0

Asociación Solidaria Para Impulsar El Desarrollo Humano (ASPI-DH ARCO IRIS)  
San Salvador, El Salvador  
\$20,000

##### Operational research to determine effective strategies for mobilization of the GMT population to access HIV prevention, treatment, and care

ISHTAR MSM  
Nairobi, Kenya  
\$26,000

#### GENERAL GMT INITIATIVE AWARDS

##### Changing faces/changing spaces conference The East African Sexual Health & Rights Initiative

(UHAI EASHRI)  
Nairobi, Kenya  
\$10,000

##### Global lube access mobilization

AIDS Foundation of Chicago  
Chicago, USA  
\$7,500

##### The Lancet series, HIV in MSM Africa, launch

Johns Hopkins University  
Baltimore, USA  
\$48,500

##### The Lancet series, HIV in MSM South America, launch

Johns Hopkins University  
Baltimore, USA  
\$15,107

##### HIV research among MSM in developing world settings

University Of Pittsburgh  
Pittsburgh, USA  
\$10,200

#### 2013 PUBLIC POLICY AWARDS

##### Harm reduction investment: analysis of the Global Fund

Principal Investigator: Jamie Bridge  
International Drug Policy Consortium  
London, United Kingdom  
\$20,000

##### Syringe exchange in the U.S., 2012–2013: assessing services in a financially challenging environment

Principal Investigator: Don C. Des Jarlais, Ph.D.  
Beth Israel Medical Center – Edmond de Rothschild Chemical Dependency Institute  
New York, NY  
\$90,000

##### Researching & advocating for civil society participation & influence in PEPFAR and Global Fund budget allocation processes in Zimbabwe

Principal Investigator: Nhlanhla Ndlovu  
Centre for Economic Governance and AIDS in Africa  
Howick, South Africa  
\$60,000

#### 2013 COMMUNITY OUTREACH AWARDS

Gay Men's Health Crisis, Inc.  
Marjorie J. Hill, Ph.D.  
New York, NY  
\$5,000

Dignitas International  
Marilyn McHarg  
Toronto, Canada  
\$130,000

Viva Cazuza  
Christina Moreira  
Rio de Janeiro, Brazil  
\$35,000

## Financial Highlights

For the year ended September 30, 2013


<b>Public Support and Revenue</b>		
Public support	\$	7,086,162
Special events		16,267,375
Planned giving		1,236,833
Government funding		4,641,817
Investment income and other revenue		710,734
<b>Total public support and revenue</b>	<b>\$</b>	<b>29,942,921</b>
<hr/>		
<b>Expenses</b>		
Research	\$	8,157,695
TREAT Asia		6,013,057
GMT Initiative		2,472,397
Public Policy		2,046,107
Public Information		3,432,973
<b>Total program services</b>	<b>\$</b>	<b>22,122,229</b>
<hr/>		
Fundraising		5,118,865
Management and general		2,321,908
<b>Total supporting services</b>	<b>\$</b>	<b>7,440,773</b>
<hr/>		
<b>Total expenses</b>	<b>\$</b>	<b>29,563,002</b>
<hr/>		
Change in net assets		379,919
Net assets, beginning of year		30,752,104
<b>Net assets, end of year</b>	<b>\$</b>	<b>31,132,023</b>

## Statement of Financial Position

<b>Assets</b>		
Cash and investments	\$	32,197,408
Pledges and receivables		13,641,950
Prepaid expenses and other assets		2,209,668
Furniture, equipment, and leasehold improvements		1,975,311
<b>Total Assets</b>	<b>\$</b>	<b>50,024,337</b>
<hr/>		
<b>Liabilities</b>		
Accounts payable and accrued expenses	\$	1,688,090
Grants and fellowships payable, net		2,200,512
Deferred support and refundable advances		13,321,993
Other long-term liabilities		1,681,719
<b>Total liabilities</b>	<b>\$</b>	<b>18,892,314</b>
<hr/>		
<b>Total net assets</b>		<b>31,132,023</b>
<hr/>		
<b>Total liabilities and net assets</b>	<b>\$</b>	<b>50,024,337</b>


### Expenses

Fundraising	\$	5,118,865
Management and general		2,321,908
Program		22,122,229
<b>Total</b>	<b>\$</b>	<b>29,942,921</b>



### Program Expenses

Research	\$	8,157,695
TREAT Asia		6,013,057
GMT Initiative		2,472,397
Public Policy		2,046,107
Public Information		3,432,973
<b>Total</b>	<b>\$</b>	<b>22,122,229</b>



## BOARD OF TRUSTEES

Fiscal year 2013

Chairman of the Board  
Kenneth Cole  
Chairman  
Kenneth Cole Productions  
New York, NY

Founding Chairman  
Mathilde Krim, Ph.D.  
Adjunct Professor  
Mailman School of Public Health  
Columbia University  
New York, NY

Vice Chairman  
Patricia J. Matson  
Senior Vice President, Communications (ret.)  
ABC, Inc.  
New York, NY

Vice Chairman  
John C. Simons  
Managing Partner  
Corporate Fuel Partners LLC  
New York, NY

Treasurer  
Wallace Sheft, C.P.A.  
Partner (ret.)  
Wurmbrand, Lerner & Sheft  
Westbury, NY

Secretary  
Mervyn F. Silverman, M.D., M.P.H.  
Crockett, CA

### TRUSTEES

Arlen H. Andelson  
Andelson Properties  
Los Angeles, CA

Harry Belafonte  
President  
Belafonte Enterprises, Inc.  
New York, NY

David Bohnett  
Chairman  
David Bohnett Foundation  
Beverly Hills, CA

Zev Braun  
President and CEO  
Braun Entertainment Group, Inc.  
Beverly Hills, CA

Jonathan S. Canno  
New York, NY

Donald A. Capoccia  
Managing Principal  
BFC Partners  
Brooklyn, NY

R. Martin Chavez, Ph.D.  
Managing Director  
Goldman, Sachs & Co.  
New York, NY

Jane B. Eisner  
President  
The Eisner Foundation  
Bel Air, CA

T. Ryan Greenawalt  
President/Founder  
Harrison Street Productions  
New York, NY

Regan Hofmann  
Policy Officer  
Washington Liaison Office  
UNAIDS  
Washington, D.C.

Michael J. Klingensmith  
CEO and Publisher  
Minneapolis Star Tribune  
Minneapolis, MN

Kevin McClatchy  
Chairman of the Board  
The McClatchy Company  
Ligonier, PA

Michele V. McNeill, Pharm.D.  
Chairman  
McNeill Family Foundation  
Long Boat Key, FL

Edward L. Milstein  
Co-Chairman  
Milstein Brothers Capital Partners  
New York, NY

Cindy D. Rachofsky  
Philanthropist  
Dallas, TX

Vincent A. Roberti  
Chairman, Roberti+White  
Washington, D.C.  
Chairman and CEO  
Palisades Media Corp.  
New York, NY

Bill Roedy  
London, UK

Raymond F. Schinazi, Ph.D., D.Sc.  
Frances Winship Walters Professor  
Director, Laboratory of Biochemical Pharmacology  
Emory University  
Decatur, GA

Alan D. Schwartz  
Executive Chairman  
Guggenheim Partners LLC  
New York, NY

Diana L. Taylor  
Managing Director  
Wolfensohn & Co. LLC  
New York, NY

Kevin Wendle  
Entrepreneur  
Paris, France

### ADJUNCT TRUSTEES

David E. Bloom, Ph.D.  
Clarence James Gamble Professor of Economics  
and Demography  
Department of Global Health and Population  
Harvard School of Public Health  
Boston, MA

Mario Stevenson, Ph.D.  
Professor of Medicine  
Chief, Division of Infectious Diseases  
Leonard M. Miller School of Medicine  
University of Miami  
Miami, FL

### TRUSTEES EMERITI

Arthur J. Ammann, M.D.  
President, Global Strategies for HIV Prevention  
Clinical Professor of Pediatrics  
University of California, San Francisco  
Medical Center  
San Rafael, CA

Arnold W. Klein, M.D.  
Professor of Medicine/Dermatology  
University of California, Los Angeles  
Beverly Hills, CA

### IN MEMORIAM

[Founding International Chairman](#)  
\*Dame Elizabeth Taylor

Sheldon W. Andelson, Esq.  
Mrs. Albert D. Lasker  
Jonathan M. Mann, M.D., M.P.H.  
Maxine Mesinger  
Pauline Phillips  
Natasha Richardson  
Allan Rosenfield, M.D.  
Peter Scott, Esq.  
Tom Stoddard  
Joel D. Weisman, D.O.

### SPECIAL APPOINTMENT

[Global Fundraising Chairman](#)  
Sharon Stone

### amfAR AMBASSADORS

Cheyenne Jackson  
Janet Jackson  
Milla Jovovich  
Liza Minnelli  
Michelle Yeoh

### BOARD COMMITTEES

[Executive Committee](#)  
Kenneth Cole, Chair  
Michael J. Klingensmith  
Mathilde Krim, Ph.D.  
Patricia J. Matson  
Vincent A. Roberti  
Wallace Sheft, C.P.A.  
Mervyn F. Silverman, M.D., M.P.H.  
John C. Simons

[Audit Committee](#)  
Wallace Sheft, C.P.A., Chair  
R. Martin Chavez, Ph.D.  
John C. Simons

[Board Development Committee](#)  
Donald A. Capoccia, Co-Chair  
Patricia J. Matson, Co-Chair  
Arlen Andelson  
David Bohnett  
Bill Roedy  
Mervyn F. Silverman, M.D., M.P.H.

[Compensation and Organizational Development Committee](#)  
John C. Simons, Chair  
Michael J. Klingensmith

#### Finance & Budget Committee

Michael J. Klingensmith, Chair  
Vincent A. Roberti  
John C. Simons

#### Fund Development Committee

Vincent A. Roberti, Chair  
Jonathan S. Canno  
Edward L. Milstein

#### Investment Committee

Michael J. Klingensmith, Chair  
R. Martin Chavez, Ph.D.  
Edward L. Milstein  
Vincent A. Roberti  
Wallace Sheft, C.P.A.  
John C. Simons

## SCIENTIFIC ADVISORY COMMITTEE

#### Mario Stevenson, Ph.D. (Chair)

Professor of Medicine  
Chief, Division of Infectious Diseases  
Leonard M. Miller School of Medicine  
University of Miami

#### Galit Alter, Ph.D.

Associate Professor  
Department of Medicine  
Harvard Medical School

#### Deborah Anderson, Ph.D.

Professor and Director  
Division of Reproductive Biology  
Boston University School of Medicine

#### Warren A. Andiman, M.D.

Professor of Pediatrics, Epidemiology  
and Public Health  
Department of Pediatrics  
Yale University School of Medicine

#### Michael Betts, Ph.D.

Associate Professor  
Department of Microbiology  
University of Pennsylvania School of Medicine

#### Jason Brechley, Ph.D.

Senior Investigator  
Vaccine Research Center  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

#### Dennis R. Burton, Ph.D.

Professor  
Department of Immunology  
The Scripps Research Institute

#### Salvatore T. Butera, D.V.M., Ph.D.

Chief Science Officer  
Scripps CHAVI-ID  
The Scripps Research Institute

#### Edward Campbell, Ph.D.

Assistant Professor  
School of Medicine  
Loyola University at Chicago

#### Alex Carballo-Dieguez, Ph.D.

Research Scientist and Associate Professor of  
Clinical Psychology  
HIV Center, NYS Psychiatric Institute  
Columbia University

#### David B. Clifford, M.D.

Professor  
Department of Neurology  
Washington University School of Medicine

#### C. Budd Colby, Ph.D.

Principal  
Colby Biomedical Consultants

#### Grant Colfax, M.D.

Director of HIV Prevention and Research  
San Francisco Department of Public Health  
Elizabeth Connick, M.D.  
Professor  
Division of Infectious Diseases  
University of Colorado

#### Deborah Jean Cotton, M.D., M.P.H.

Professor of Medicine  
Department of Medicine  
Boston University School of Medicine

#### Bryan Richard Cullen, Ph.D.

Professor  
Department of Genetics  
Duke University Medical Center

#### Susanna Cunningham-Rundles, Ph.D.

Professor of Immunology  
Department of Pediatrics  
Cornell University Medical College

#### Richard Thomas D'Aquila, M.D.

Director, Northwestern HIV Translational  
Research Center  
The Howard Taylor Ricketts Professor of  
Medicine, Division of Infectious Diseases,  
Department of Medicine  
Northwestern University

#### Sherry Deren, Ph.D.

Director  
Center for Drug Use and HIV Research  
New York University College of Nursing

#### Roger Detels, M.D., M.S.

Professor of Epidemiology  
School of Public Health  
University of California, Los Angeles

#### Carl W. Dieffenbach, Ph.D.

Director  
Division of AIDS (DAIDS)  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

#### Daniel C. Douek, M.D., Ph.D.

Chief, Human Immunology Section  
Vaccine Research Center  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

#### D. Peter Drotman, M.D., M.P.H.

Editor in-Chief  
Emerging Infectious Diseases  
Centers for Disease Control and Prevention

#### Anke A. Ehrhardt, Ph.D.

Director and Professor  
Department of Psychiatry  
Columbia University, NY State Psychiatric Institute

#### Homayoon Farzadegan, Ph.D.

Professor  
Department of Epidemiology  
The Johns Hopkins University

#### Dianne M. Finkelstein, Ph.D.

Director of Biostatistics  
Cancer Center Biostatistics  
Massachusetts General Hospital and Harvard  
Medical School

#### Gerald Herbert Friedland, M.D.

Professor and Director, AIDS Program  
Department of Internal Medicine  
Yale School of Medicine

#### Howard E. Gendelman, M.D.

David T. Purtilo Professor of Pathology and  
Microbiology  
Department of Pathology and Microbiology  
University of Nebraska Medical Center

#### Nancy L. Haigwood, Ph.D.

Director and Senior Scientist  
Division of Pathobiology and Immunology  
Oregon National Primate Research Center

#### Timothy Henrich, M.D.

Instructor in Medicine, Associate Physician  
Department of Medicine, Infectious Diseases  
Brigham and Women's Hospital

#### Charles H. Hinkin, Ph.D.

Associate Professor  
Department of Psychiatry and Biobehavioral  
Science  
University of California School of Medicine

#### David Ho, M.D.

Scientific Director, Chief Executive Officer  
Aaron Diamond AIDS Research Center

#### Thomas J. Hope, Ph.D.

Professor  
Department of Cell and Molecular Biology  
Northwestern University, Feinberg School of  
Medicine

#### Shiu-Lok Hu, Ph.D.

Professor  
School of Pharmacy  
University of Washington

#### Jonathan Karn, Ph.D.

Director  
Case Center for AIDS Research  
Case Western Reserve University

#### Vineet KewalRamani, Ph.D.

Chief, Model Development Section  
HIV Drug Resistance Program  
National Cancer Institute  
National Institutes of Health

#### Richard Kornbluth, M.D., Ph.D.

President and Chief Scientific Officer  
Multimeric Biotherapeutics, Inc.

#### Richard A. Koup, M.D.

Chief, Immunology Laboratory  
Vaccine Research Center  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

#### Nathaniel R. Landau, Ph.D.

Professor  
Department of Microbiology  
New York University School of Medicine

#### Alan L. Landay, Ph.D.

Professor and Associate Chairman  
Department of Immunology and Microbiology  
Rush-Presbyterian-St. Luke's Medical Center



**Michael Lederman, M.D.**  
Scott R. Inkley Professor of Medicine, Department of Medicine and Co-Director, Center for AIDS Research Case Western Reserve University

**Tun-Hou Lee, D.Sc.**  
Professor of Virology  
Department of Immunology and Infectious Diseases  
Harvard School of Public Health

**Michael J. Leibowitz, M.D., Ph.D.**  
Professor  
Department of Molecular Genetics and Microbiology  
University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School

**Robert J. Levine, M.D.**  
Professor of Medicine  
Center for Interdisciplinary Research on AIDS  
Yale University

**Mathias Lichterfeld, M.D.**  
Assistant Professor of Medicine  
Department of Medicine  
Massachusetts General Hospital

**Judy Lieberman, M.D., Ph.D.**  
Senior Investigator  
Immune Disease Institute  
Professor of Pediatrics  
Harvard Medical School

**H. Kim Lyster, M.D.**  
Professor in Surgery, Immunology, Pathology  
Duke Comprehensive Cancer Institute  
Duke University Medical Center

**Frank Maldarelli, M.D., Ph.D.**  
Investigator  
HIV DRP Host-Virus Interactions Branch  
National Cancer Institute  
National Institutes of Health

**David M. Margolis, M.D.**  
Professor of Microbiology, Medicine and Public Health  
School of Medicine  
University of North Carolina at Chapel Hill

**Martin H. Markowitz, M.D.**  
Staff Investigator  
Aaron Diamond AIDS Research Center

**Kenneth Hugh Mayer, M.D.**  
Infectious Disease Attending & Director of HIV Prevention Research  
Beth Israel Deaconess Medical Center  
Professor of Medicine  
Harvard Medical School  
Medical Research Director, Co-Chair  
The Fenway Institute/Fenway Health

**Joseph M. McCune, M.D., Ph.D.**  
Professor of Medicine  
Division of Experimental Medicine  
University of California, San Francisco

**Donna Mildvan, M.D.**  
Chief, Division of Infectious Diseases  
Department of Medicine  
Beth Israel Medical Center

**Jay A. Nelson, Ph.D.**  
Professor and Director  
Division of Pathobiology and Immunology  
Oregon Health Sciences University

**Nancy Padian, Ph.D., M.P.H.**  
Executive Director  
Women's Global Health Imperative  
RTI International  
Professor, Department of Obstetrics, Gynecology and Reproductive Sciences and Department of Epidemiology and Biostatistics  
University of California, San Francisco

**Savita Pahwa, M.D.**  
Director  
Microbiology and Immunology  
Leonard M. Miller School of Medicine  
University of Miami

**Tristram G. Parslow, M.D., Ph.D.**  
William Patterson Timmie Professor and Chair  
Department of Pathology and Laboratory Medicine  
Emory University School of Medicine

**Matija Peterlin, M.D.**  
Professor of Medicine, Microbiology and Immunology  
Department of Medicine  
University of California, San Francisco

**Lynn Pulliam, Ph.D.**  
Professor  
Department of Laboratory Medicine and Medicine  
University of California, San Francisco  
Veterans Affairs Medical Center

**Lee Ratner, M.D., Ph.D.**  
Professor  
Department of Medicine  
Washington University School of Medicine

**Andrew Rice, Ph.D.**  
Professor  
Department of Molecular Virology and Microbiology  
Baylor College of Medicine

**Melissa Robbiani, Ph.D.**  
Senior Scientist and Director of Biomedical HIV Research  
Center for Biomedical Research  
Population Council

**Ruth M. Ruprecht, M.D., Ph.D.**  
Professor of Medicine  
Department of Cancer Immunology and AIDS  
Dana-Farber Cancer Institute and Harvard Medical School

**Frederick A. Schmitt, Ph.D.**  
Associate Professor  
Departments of Neurology, Psychiatry and Psychology  
University of Kentucky Medical Center

**Gerald Schochetman, Ph.D.**  
Director, AIDS Research and Retrovirus Discovery  
Abbott Laboratories

**Robert Turner Schooley, M.D.**  
Academic Vice Chair  
Professor and Head  
Department of Medicine/Division of Infectious Diseases  
University of California, San Diego

**Gail Skowron, M.D.**  
Associate Professor of Medicine  
Department of Medicine, Division of Infectious Diseases  
Roger Williams Medical Center

**Leonidas Stamatatos, Ph.D.**  
Full Member and Director of Viral Vaccines Program  
Seattle Biomedical Research Institute

**Ernest F. Terwilliger, Ph.D.**  
Assistant Professor  
Beth Israel Deaconess Medical Center

**Barbara Visscher, M.D., Dr.P.H.**  
Professor of Epidemiology  
Department of Epidemiology  
University of California, Los Angeles

**David Vlahov, Ph.D.**  
Director  
Center for Urban Epidemiologic Studies  
New York Academy of Medicine

**David J. Volsky, Ph.D.**  
Professor and Director  
Department of Pathology and Medicine  
St. Luke's-Roosevelt Hospital Center and Columbia University

**Steven S. Witkin, Ph.D.**  
Professor and Director  
Department of Obstetrics and Gynecology  
Weill Medical College of Cornell University

**Peter R. Wolfe, M.D.**  
Associate Clinical Professor  
University of California, Los Angeles

**Richard T. Wyatt, Ph.D.**  
Professor of Immunology  
IAVI Center for Neutralizing Antibodies  
The Scripps Research Institute

## PROGRAM ADVISORY COUNCIL

**Mervyn Silverman, M.D., M.P.H. (Chairman)**  
President  
Mervyn F. Silverman Associates, Inc.

**David Bloom, Ph.D. (Co-Chairman)**  
Clarence James Gamble Professor of Economics and Demography  
Department of Global Health and Population  
Harvard School of Public Health

**Mario Stevenson, Ph.D. (Co-Chairman)**  
Professor of Medicine  
Chief, Division of Infectious Diseases  
University of Miami  
Leonard M. Miller School of Medicine

**Tim Brown, Ph.D.**  
Senior Fellow  
The East-West Center

**Daria J. Hazuda, Ph.D.**  
Vice President of Scientific Affairs for Infectious Disease  
Merck & Company, Inc.

**Kenneth H. Mayer, M.D.**  
Infectious Disease Attending & Director of HIV  
Prevention Research  
Beth Israel Deaconess Medical Center  
Visiting Professor of Medicine  
Harvard Medical School  
Medical Research Director  
The Fenway Institute/Fenway Health

**Jeffrey L. Sturchio, Ph.D.**  
Senior Partner  
Rabin Martin, New York  
Visiting Scholar  
The Institute for Applied Economics, Global Health  
and the Study of Business Enterprise  
Johns Hopkins University  
Member, The Council on Foreign Relations

**Phill Wilson**  
Chief Executive Officer and President  
The Black AIDS Institute

## MANAGEMENT GROUP

**Kevin Robert Frost**  
Chief Executive Officer

**Anthony Ancona**  
Vice President and Director, Human Resources

**Susan J. Blumenthal, M.D., M.P.A.**  
Senior Policy and Medical Advisor

**Gregory Boroff, C.A.E., C.F.R.E.**  
Vice President and Director, Development

**Chris Collins, M.P.P.**  
Vice President and Director, Public Policy

**Bradley Jensen**  
Chief Financial Officer

**Rowena Johnston, Ph.D.**  
Vice President and Director, Research

**Jeffrey Laurence, M.D.**  
Senior Scientific Consultant for Programs

**John F. Logan, Ph.D., J.D.**  
Vice President and General Counsel

**AnnMari Shannahan**  
Vice President, Public Information

**Annette Sohn, M.D.**  
Vice President and Director, TREAT Asia

**amfAR, The Foundation for AIDS Research**

**NEW YORK**

120 Wall Street, 13th Floor  
New York, NY 10005-3908  
(212) 806-1600 (tel)  
(212) 806-1601 (fax)

**WASHINGTON, D.C.**

1150 17th Street, NW  
Suite 406  
Washington, DC 20036-4622  
(202) 331-8600 (tel)  
(202) 331-8606 (fax)

**BANGKOK, THAILAND**

TREAT Asia  
Exchange Tower  
388 Sukhumvit Road, Suite 2104  
Klongtoey, Bangkok 10110  
Thailand  
+66 (0)2 663 7561 (tel)  
+66 (0)2 663 7562 (fax)

**[www.amfar.org](http://www.amfar.org)**



[bbb.org/charity](http://bbb.org/charity)

amfAR meets the BBB  
Wise Giving Alliance's  
Standards for Charity  
Accountability.



★★★★  
**CHARITY NAVIGATOR**  
Four Star Charity